THE CLINICAL IMPORTANCE OF ERYTHROCYTE PHENOTYPING IN THE ABO AND RHD SYSTEMS
DOI:
https://doi.org/10.66104/jfvgxc56Keywords:
Erythrocyte phenotyping, Blood typing, Alloimmunization, Transfusion safety, ABO and RhDAbstract
Considering that transfusion safety directly depends on donor–recipient compatibility, this study addressed the need to understand the clinical importance of erythrocyte phenotyping within the ABO and RhD systems. Objective: To identify the main deterministic factors that demonstrate the relevance of this practice as an essential tool for preventing alloimmunization and adverse transfusion reactions. Methodology: An integrative literature review with comparative analysis of the findings is carried out, based on articles published between 2020 and 2025 in the SciELO and PubMed databases. Results: Seventeen studies were selected, revealing that the systematic application of erythrocyte phenotyping significantly reduces the risk of incompatibilities, improves blood stock management, and strengthens hemovigilance policies. Conclusion: Erythrocyte phenotyping is an indispensable tool for transfusion safety and for achieving more precise, ethical, and humanized clinical practice.
Downloads
References
AMINI, M et al. Association of Micro RNA-155 with Alloimmunization in Transfusion-Dependent Thalassemia Patients. Hemoglobin, [S.l.], v. 49, n. 4, p. 268-274, 2025. Disponível em: https://www.tandfonline.com/doi/full/10.1080/03630269.2025.2533229. Acesso em: 16 nov. 2025.
BEAUFORT, J et al. Transfusion strategy and allo-immunization to red blood cell antigens after allogeneic hematopoietic stem cell transplantation with partial donor/recipient Rh matching. Transfusion Clinique et Biologique, [S.l.], v. 32, n. 3, p. 292-297, 2025. Disponível em: https://pubmed.ncbi.nlm.nih.gov/40480293/. Acesso em: 16 nov. 2025.
BENDETTI, V et al. Frequência de anticorpos irregulares identificados em pacientes atendidos em um hemonúcleo no sudoeste do Paraná no ano de 2017. Arquivos de Ciências da Saúde UNIPAR, Umuarama, v. 24, n. 3, p. 133-138, 2020. Disponível em: https://revistas.unipar.br/index.php/saude/article/view/7542. Acesso em: 16 nov. 2025.
BRASIL. Agência Nacional de Vigilância Sanitária. Manual técnico de hemovigilância: investigação das reações transfusionais imediatas e tardias não infecciosas. Brasília: Anvisa, 2007. Disponível em: https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/monitoramento/hemovigilancia/manual-tecnico-de-hemovigilancia-investigacao-das-reacoes-transfusionais-imediatas-e-tardias-nao-infecciosas.pdf. Acesso em: 16 nov. 2025.
BRASIL. Agência Nacional de Vigilância Sanitária. Resolução da Diretoria Colegiada – RDC nº 34, de 11 de junho de 2014. Dispõe sobre as Boas Práticas no Ciclo do Sangue. Diário Oficial da União, Brasília, DF, 16 jun. 2014. Disponível em: https://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2014/rdc0034_11_06_2014.pdf. Acesso em: 16 nov. 2025.
BRASIL. Ministério da Saúde. Guia do cadastro nacional de sangue raro. Brasília: Ministério da Saúde, 2021. Disponível em: https://bvsms.saude.gov.br/bvs/publicacoes/guia_cadastro_nacional_sangue_raro.pdf. Acesso em: 16 nov. 2025.
BRASIL. Ministério da Saúde. Guia para o uso de hemocomponentes. 2. ed. Brasília: Ministério da Saúde, 2011. Disponível em: https://bvsms.saude.gov.br/bvs/publicacoes/guia_uso_hemocomponentes_2ed.pdf. Acesso em: 16 nov. 2025.
BRASIL. Ministério da Saúde. Manual técnico de hemovigilância. Brasília: Ministério da Saúde, 2004. Disponível em: https://bvsms.saude.gov.br/bvs/publicacoes/MANUAL_TECNICO_HEMOVIGILANCIA_2004.pdf. Acesso em: 16 nov. 2025.
BRASIL. Ministério da Saúde. Segurança transfusional: hemoterapia no Centro-Oeste e Norte do Brasil. Brasília: Ministério da Saúde, 2016. Disponível em: https://bvsms.saude.gov.br/bvs/publicacoes/seguranca_transfusional_hemoterapia_centro_oeste_norte_brasil.pdf. Acesso em: 16 nov. 2025.
CAMPOS, A et al. Conhecimento de usuários de redes sociais sobre tipagem sanguínea. Revista Ciência e Saúde On-line, [S.l.], v. 8, n. 3, 2023. Disponível em: https://revistaeletronicafunvic.org/index.php/c14ffd10/article/view/478. Acesso em: 16 nov. 2025.
CHATTERJEE, A et al. Anti-A and anti-B titers in A, B and O whole blood donors: Beyond "dangerous O". Transfusion Clinique et Biologique, [S.l.], v. 31, n. 4, p. 195-200, 2024. DOI: 10.1016/j.tracli.2024.06.002. Disponível em: https://www.sciencedirect.com/science/article/pii/S1246782024000580. Acesso em: 16 nov. 2025.
CHORNENKYY, Y et al. Alloimmunization Against RBC Antigens Is Not Associated With Decreased Survival in Liver Transplant Recipients. American Journal of Clinical Pathology, [S.l.], v. 159, n. 3, p. 255-262, 2023. DOI: 10.1093/ajcp/aqac161. Disponível em: https://pubmed.ncbi.nlm.nih.gov/38909678/. Acesso em: 16 nov. 2025.
DELBAUGH, R. et al. Why do people still make anti-D over 50 years after the introduction of Rho(D) immune globulin? A Biomedical Excellence for Safer Transfusion (BEST) Collaborative study. Transfusion, [S.l.], v. 65, n. 5, p. 957-967, 2025. DOI: 10.1111/trf.18168. Disponível em: https://pubmed.ncbi.nlm.nih.gov/40059673/. Acesso em: 16 nov. 2025.
DREYFUSS, E. et al. The prevalence and timing of seroconversion during pregnancy: A retrospective study to enable safe transfusion. Transfusion, [S.l.], v. 65, n. 9, p. 1707-1715, 2025. DOI: 10.1111/trf.18446. Disponível em: https://pubmed.ncbi.nlm.nih.gov/40708459/. Acesso em: 16 nov. 2025.
GAMMON, R et al. RhD-Alloimmunization in Adult and Pediatric Trauma Patients. Transfusion Medicine Reviews, [S.l.], v. 38, n. 4, p. 150842, 2024. DOI: 10.1016/j.tmrv.2024.150842. Disponível em: https://pubmed.ncbi.nlm.nih.gov/39127022/. Acesso em: 16 nov. 2025.
GIBSON, N et al. Impact of HLA alloimmunization in gene-modified autologous stem cell transplant for transfusion-dependent thalassemia. Blood, [S.l.], v. 145, n. 22, p. 2666-2670, 2025. DOI: 10.1182/blood.2024024131. Disponível em: https://pubmed.ncbi.nlm.nih.gov/40089998/. Acesso em: 16 nov. 2025.
HERMES, J.; MARTINELLO, F. Garantia da qualidade dos exames de fenotipagem ABO e RhD: revisão de escopo. Brazilian Journal of Health Review, [S. l.], v. 6, n. 2, p. 6069–6087, 2023. DOI: 10.34119/bjhrv6n2-129. Disponível em: https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/58302. Acesso em: 16 nov. 2025.
LOPES, C; DURAN, J. A Importância do teste de antiglobulina direto na prática transfusional de rotina. ABO, [S.l.], n. 15, p. 7-13, 2003. Disponível em: http://ipst.pt/files/IPST/INFORMACAO_DOCUMENTACAO/AB0_15_2003_pag_7a13.pdf. Acesso em: 16 nov. 2025.
MARTINS, P. et al. Frequência de anticorpos irregulares em politransfundidos no Hemocentro Regional de Uberaba-MG, de 1997 a 2005. Revista Brasileira de Hematologia e Hemoterapia, [S. l.], v. 30, n. 4, p. 272–276, 2008. DOI: 10.1590/S1516-84842008000400006. Disponível em: https://www.scielo.br/j/rbhh/a/8PgXN7VxY7qbTSGPHHj9RGw/abstract/?lang=en. Acesso em: 16 nov. 2025.
MATHUR, A. et al. A multicenter prospective observational study on the use of type and screen method versus conventional type and crossmatch policy for pre-transfusion testing in the Indian population. Immunohematology, [S.l.], v. 38, n. 3, p. 100-105, 2022. DOI: 10.21307/immunohematology-2022-050. Disponível em: https://pubmed.ncbi.nlm.nih.gov/36190198/. Acesso em: 16 nov. 2025.
MAZZA, B. et al. Blood transfusions in septic shock: is 7.0g/dL really the appropriate threshold? Revista Brasileira de Terapia Intensiva, [S.l.], v. 27, n. 1, p. 36-42, 2015. Disponível em: https://pubmed.ncbi.nlm.nih.gov/25909311/. Acesso em: 16 nov. 2025.
MONTEIRO, L. et al. Phenotype frequencies of ABO, Rh and Kell blood group systems in blood donors in the metropolitan region of Belém-PA. RBAC, [S.l.], v. 52, n. 4, 2020. Disponível em: https://docs.bvsalud.org/biblioref/2021/06/1247717/rbac-vol-52-4-2020-ref-955-1.pdf. Acesso em: 16 nov. 2025.
MORAES, S. et al. Frequência dos grupos sanguíneos ABO e RhD entre alunos de faculdade privada no estado de São Paulo. Hematology, Transfusion and Cell Therapy, [S.l.], v. 45, p. S987-S988, 2023. Disponível em: https://www.sciencedirect.com/science/article/pii/S2531137923019491. Acesso em: 16 nov. 2025.
PANDEY, P. et al. A retrospective observational study to estimate the risk of HLA alloimmunization with blood transfusion: Can the risk be reduced by leucodepletion? Immunobiology, [S.l.], v. 228, n. 5, p. 152727, 2023. DOI: 10.1016/j.imbio.2023.152727. Disponível em: https://pubmed.ncbi.nlm.nih.gov/37586300/. Acesso em: 16 nov. 2025.
PERRY, H.; PERRY, W. Analysis of haemovigilance reports reveals 12.5% of acute haemolytic transfusion reactions are attributed to antibodies to low-incidence antigens. Vox Sanguinis, [S.l.], v. 120, n. 9, p. 928-934, 2025. DOI: 10.1111/vox.13707. Disponível em: https://pubmed.ncbi.nlm.nih.gov/40754322/. Acesso em: 16 nov. 2025.
SANTOS, S et al. Avaliação do conhecimento de uma população idosa sobre os tipos sanguíneos. Revista Saúde & Ciência, [S.l.], v. 7, n. 1, p. 26-34, 2018. Disponível em: https://www.rsc.revistas.ufcg.edu.br/index.php/rsc/article/view/78. Acesso em: 16 nov. 2025.
SILVA, T. et al. Análise da distribuição de variantes de d-fraco em doadores de sangue brasileiros: implicações para a imunoprofilaxia RHD. Hematology, Transfusion and Cell Therapy, v. 46, p. S868-S869, 2024. Disponível em: https://www.sciencedirect.com/science/article/pii/S2531137924018078. Acesso em: 16 nov. 2025.
VIJAYANARAYANAN, A et al. Lack of alloimmunization to the D antigen in D-negative orthotopic liver transplant recipients receiving D-positive red blood cells perioperatively. Vox Sanguinis, [S.l.], v. 117, n. 8, p. 1043-1047, 2022. DOI: 10.1111/vox.13288. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35393659/. Acesso em: 16 nov. 2025.
WANG, L. et al. Red blood cell alloimmunization in transfused patients with myelodysplastic syndromes: a retrospective study from northern China. Laboratory Medicine, [S.l.], v. 56, n. 1, p. 22-30, 2025. DOI: 10.1093/labmed/lmae053. Disponível em: https://academic.oup.com/labmed/article/56/1/22/7727304. Acesso em: 16 nov. 2025.
YU, T. et al. Optimized strategy to mitigate daratumumab interference in blood bank testing: Reducing cost and time. American Journal of Clinical Pathology, [S.l.], v. 164, n. 3, p. 283-288, 2025. DOI: 10.1093/ajcp/aqae080. Disponível em: https://academic.oup.com/ajcp/article/164/3/283/7695749. Acesso em: 16 nov. 2025.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Gabriel Alves de Almeida Vilar Alves de Almeida, Carlos André dos Santos Silva
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish in this journal agree to the following terms:
Authors retain copyright and grant the journal the right of first publication, with the work simultaneously licensed under the Creative Commons Attribution License, which permits the sharing of the work with proper acknowledgment of authorship and initial publication in this journal;
Authors are authorized to enter into separate, additional agreements for the non-exclusive distribution of the version of the work published in this journal (e.g., posting in an institutional repository or publishing it as a book chapter), provided that authorship and initial publication in this journal are properly acknowledged, and that the work is adapted to the template of the respective repository;
Authors are permitted and encouraged to post and distribute their work online (e.g., in institutional repositories or on their personal websites) at any point before or during the editorial process, as this may lead to productive exchanges and increase the impact and citation of the published work (see The Effect of Open Access);
Authors are responsible for correctly providing their personal information, including name, keywords, abstracts, and other relevant data, thereby defining how they wish to be cited. The journal’s editorial board is not responsible for any errors or inconsistencies in these records.
PRIVACY POLICY
The names and email addresses provided to this journal will be used exclusively for the purposes of this publication and will not be made available for any other purpose or to third parties.
Note: All content of the work is the sole responsibility of the author and the advisor.
